デフォルト表紙
市場調査レポート
商品コード
1600018

細胞・遺伝子治療の臨床試験市場:タイプ、フェーズ、用途、エンドユーザー別-2025-2030年の世界予測

Cell & Gene Therapy Clinical Trials Market by Type (Cell Therapy Clinical Trials, Gene Therapy Clinical Trials), Phase (Phase I, Phase II, Phase III), Application, End-User - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 188 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
細胞・遺伝子治療の臨床試験市場:タイプ、フェーズ、用途、エンドユーザー別-2025-2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 188 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞・遺伝子治療の臨床試験市場は、2023年に92億米ドルと評価され、2024年には104億8,000万米ドルに達すると予想され、CAGR 14.61%で成長し、2030年には239億1,000万米ドルに達すると予測されています。

細胞治療と遺伝子治療は、遺伝子レベルでの治療、予防、潜在的な治癒に焦点を当てた臨床試験における最先端の開発です。これらの治療の範囲は腫瘍学から希少遺伝性疾患にまで及び、疾患治療プロトコルに変革の可能性を提供しています。これらの治療法は、単に症状を和らげるだけでなく、疾患の根本原因に対処する独自のメカニズムにより、複雑で慢性的な疾患の持続可能で長期的な管理や治癒への道を開くために必要です。これらの治療法の最終用途は、病院、専門治療センター、研究機関などであり、ヘルスケアやバイオテクノロジーなど複数のセクターにまたがっています。市場の主なハイライトは、技術の進歩や規制環境の整備によって、製薬会社、バイオテクノロジー企業、学術機関の間で投資や提携が急増していることです。慢性疾患の増加や高齢化により、革新的な治療に対する需要が高まっており、ビジネスチャンスは豊富にあります。しかし、研究開発費の高騰、複雑な規制状況、製造・物流のハードルといった課題も残っており、これが市場の成長を阻害しています。さらに、適切な保険償還の枠組みの欠如や熟練労働力の必要性も大きな制約となっています。継続的な技術革新への注力は不可欠であり、ベクター設計、CRISPRのような遺伝子編集技術、治療の有効性を高めコストを削減するためのスケーラブルな生産方法など、改良の余地は十分にあります。大手製薬企業がパイプラインと能力ポートフォリオを強化するために中小バイオテクノロジー企業を買収するため、市場の性質は統合に傾いています。事業を成功させるためには、研究開発のための戦略的パートナーシップを重視し、最先端の製造技術に投資し、個別化医療のアプローチを支持する必要があります。臨床試験デザインを最適化し、多用途の薬事規制経路を模索するために、規制当局と早期に関わることで、市場への参入と拡大を容易にすることができます。

主な市場の統計
基準年[2023] 92億米ドル
予測年[2024] 104億8,000万米ドル
予測年[2030] 239億1,000万米ドル
CAGR(%) 14.61%

市場力学:急速に進化する細胞・遺伝子治療の臨床試験市場の主要市場インサイトを公開

細胞・遺伝子治療の臨床試験市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • がん研究における細胞・遺伝子治療の応用拡大
    • 世界中で慢性疾患の有病率が上昇
    • バイオ医薬品企業による細胞ベースの研究への投資活動の増加
  • 市場抑制要因
    • 遺伝子を安全かつ効果的に人体に導入する技術の複雑さ
  • 市場機会
    • 細胞・遺伝子治療に対する政府からの規制認可の増加
    • 細胞・遺伝子治療の臨床試験に対する先端技術の採用の増加
  • 市場の課題
    • 治療に対する患者の反応のばらつきに関する問題

ポーターの5つの力:細胞・遺伝子治療の臨床試験市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:細胞・遺伝子治療の臨床試験市場における外部からの影響の把握

外部マクロ環境要因は、細胞・遺伝子治療の臨床試験市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析細胞・遺伝子治療の臨床試験市場における競合情勢の把握

細胞・遺伝子治療の臨床試験市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス細胞・遺伝子治療の臨床試験市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、細胞・遺伝子治療の臨床試験市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨細胞・遺伝子治療の臨床試験市場における成功への道筋を描く

細胞・遺伝子治療の臨床試験市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • がん調査における細胞・遺伝子治療の応用拡大
      • 世界中で慢性疾患の罹患率が上昇
      • 細胞ベースの調査に対するバイオ医薬品企業の投資活動の増加
    • 抑制要因
      • 遺伝子を人体に安全かつ効果的に送達するための技術的な複雑さ
    • 機会
      • 細胞・遺伝子治療に対する政府からの規制承認が増加
      • 細胞・遺伝子治療の臨床試験の先進技術の採用拡大
    • 課題
      • 治療に対する患者の反応のばらつきに関連する問題
  • 市場セグメンテーション分析
    • タイプ:がんや遺伝性疾患の治療における同種細胞療法の重要性の高まり
    • エンドユーザー:効率性と拡張性により、契約調査機関における細胞・遺伝子治療の臨床試験の適用が増加
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 細胞・遺伝子治療の臨床試験市場:タイプ別

  • 細胞治療臨床試験
    • 同種細胞療法
    • 自己細胞療法
    • CAR-T細胞療法
    • 間葉系幹細胞療法
  • 遺伝子治療臨床試験
    • アンチセンスオリゴヌクレオチドに基づく遺伝子治療
    • CRISPRベースの遺伝子治療
    • 非ウイルスベクター遺伝子治療
    • ウイルスベクター遺伝子治療

第7章 細胞・遺伝子治療の臨床試験市場フェーズ別

  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第8章 細胞・遺伝子治療の臨床試験市場:用途別

  • 心臓病学
  • 皮膚科
  • 内分泌、代謝、遺伝
  • 消化器内科
  • 血液学
  • 免疫学と炎症
  • 感染症
  • 筋骨格
  • 神経学
  • 腫瘍学
  • 眼科

第9章 細胞・遺伝子治療の臨床試験市場:エンドユーザー別

  • 学術調査機関
  • 契約調査機関(CRO)
  • 病院と診療所
  • 製薬会社

第10章 南北アメリカの細胞・遺伝子治療の臨床試験市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の細胞・遺伝子治療の臨床試験市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの細胞・遺伝子治療の臨床試験市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • シンシナティ小児病院、シャロンビルに6,000万米ドル規模の応用遺伝子・細胞治療センターを開設
    • プレミア調査とバイオセントリクの戦略的提携により、革新的な細胞治療のIND申請前のスケジュールと臨床応用が加速
    • アステラス製薬、独占的ライセンシングとがん細胞治療の開発のためポセイダ・セラピューティクスに5,000万米ドルを投資
  • 戦略分析と提言

企業一覧

  • Accell Clinical Research, LLC
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Atlant Clinical Ltd.
  • Biogen Inc.
  • Charles River Laboratories International, Inc.
  • CORESTEM, Inc.
  • CTI Clinical Trial and Consulting Services, Inc.
  • Dendreon Pharmaceuticals LLC
  • HELIXMITH Co., Ltd.
  • ICON PLC
  • IQVIA Inc.
  • Kolon TissueGene, Inc.
  • Laboratory Corporation of America Holdings
  • Medpace Holdings, Inc.
  • Novartis AG
  • Novotech Pty Limited
  • Parexel International Corporation
  • Ppd, Inc.
  • ProPharma Group Holdings, LLC
  • PSI CRO
  • SGS S.A.
  • Syneos Health, Inc.
  • Veristat, LLC
  • Wuxi AppTec Inc.
図表

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL & GENE THERAPY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL & GENE THERAPY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE-BASED GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CRISPR-BASED GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ENDOCRINE, METABOLIC, & GENETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 143. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 144. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 145. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 149. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 150. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. THAILAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 155. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 156. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 157. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. VIETNAM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 168. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 169. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 170. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. DENMARK CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 174. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 175. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. EGYPT CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 180. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 181. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 182. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. FINLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 186. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 187. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 188. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. FRANCE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 192. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 193. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 194. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. GERMANY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 198. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 199. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 200. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. ISRAEL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 204. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 205. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 206. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. ITALY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 210. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 212. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NETHERLANDS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 216. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 217. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 218. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. NIGERIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 222. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 223. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 224. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. NORWAY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 228. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 229. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 230. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. POLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 234. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 235. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 236. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. QATAR CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 240. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 241. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 242. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. RUSSIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 246. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 248. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SAUDI ARABIA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 258. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 259. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 260. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SPAIN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 264. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 265. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 266. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. SWEDEN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 270. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 272. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. SWITZERLAND CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 276. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 277. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 278. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. TURKEY CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED ARAB EMIRATES CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY CLINICAL TRIALS, 2018-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 290. UNITED KINGDOM CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)

TABLE 2

目次
Product Code: MRR-0D217D5AEB5A

The Cell & Gene Therapy Clinical Trials Market was valued at USD 9.20 billion in 2023, expected to reach USD 10.48 billion in 2024, and is projected to grow at a CAGR of 14.61%, to USD 23.91 billion by 2030.

Cell and gene therapies represent cutting-edge developments in clinical trials focused on treating, preventing, or potentially curing condition-drivers at the genetic level. The scope of these therapies extends from oncology to rare genetic disorders, offering transformative potential in disease treatment protocols. These therapies are necessary due to their unique mechanisms that address root causes of diseases rather than merely alleviating symptoms, paving the way for sustainable, long-term management or cure of complex and chronic conditions. Application of these therapies spans multiple sectors, including healthcare and biotechnology, with end-use in hospitals, specialized treatment centers, and research institutions. Market insights highlight a surge in investment and collaborations between pharmaceutical companies, biotech firms, and academic institutions driven by technological advancements and supportive regulatory environments, which act as key growth influencers. Opportunities are abundant with increasing incidences of chronic diseases and an aging population, driving the demand for innovative treatments. However, challenges persist, such as high R&D costs, complex regulatory landscapes, and manufacturing and logistical hurdles, which can impede market growth. Additionally, the lack of appropriate reimbursement frameworks and the need for skilled workforce pose significant limitations. Focus on continuous innovation is essential, with ample scope for improvements in vector design, gene editing technologies like CRISPR, and scalable production methods to enhance therapy efficacy and reduce costs. The nature of the market leans towards consolidation, as larger pharmaceutical entities acquire smaller biotechs to bolster pipelines and capability portfolios. To thrive, businesses should focus on strategic partnerships for R&D, invest in cutting-edge manufacturing technologies, and champion personalized medicine approaches. Engaging with regulatory bodies early for optimizing trial designs and seeking versatile regulatory pathways could ease market entry and expansion, while targeting niche markets with high unmet needs would provide a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 9.20 billion
Estimated Year [2024] USD 10.48 billion
Forecast Year [2030] USD 23.91 billion
CAGR (%) 14.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Clinical Trials Market

The Cell & Gene Therapy Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing application of cell & gene therapy in cancer research
    • Rising prevalence of chronic disease across the globe
    • Increasing investment activities by biopharmaceutical companies for cell-based research
  • Market Restraints
    • Technological complexity of delivering genes into the human body safely and effectively
  • Market Opportunities
    • Growing regulatory approvals from the government for cell & gene therapies
    • Increasing adoption of advanced technologies for cell & gene therapy clinical trials
  • Market Challenges
    • Issues associated with variability in patient responses to therapies

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Clinical Trials Market

A detailed market share analysis in the Cell & Gene Therapy Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Clinical Trials Market

A strategic analysis of the Cell & Gene Therapy Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include Accell Clinical Research, LLC, Alnylam Pharmaceuticals, Inc., Amgen Inc., Atlant Clinical Ltd., Biogen Inc., Charles River Laboratories International, Inc., CORESTEM, Inc., CTI Clinical Trial and Consulting Services, Inc., Dendreon Pharmaceuticals LLC, HELIXMITH Co., Ltd., ICON PLC, IQVIA Inc., Kolon TissueGene, Inc., Laboratory Corporation of America Holdings, Medpace Holdings, Inc., Novartis AG, Novotech Pty Limited, Parexel International Corporation, Ppd, Inc., ProPharma Group Holdings, LLC, PSI CRO, SGS S.A., Syneos Health, Inc., Veristat, LLC, and Wuxi AppTec Inc..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cell Therapy Clinical Trials and Gene Therapy Clinical Trials. The Cell Therapy Clinical Trials is further studied across Allogeneic Cell Therapy, Autologous Cell Therapy, CAR-T Cell Therapy, and Mesenchymal Stem Cell Therapy. The Gene Therapy Clinical Trials is further studied across Antisense Oligonucleotide-Based Gene Therapy, CRISPR-Based Gene Therapy, Non-Viral Vector Gene Therapy, and Viral Vector Gene Therapy.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Application, market is studied across Cardiology, Dermatology, Endocrine, Metabolic, & Genetic, Gastroenterology, Hematology, Immunology & Inflammation, Infectious Diseases, Musculoskeletal, Neurology, Oncology, and Ophthalmology.
  • Based on End-User, market is studied across Academic & Research Institutes, Contract Research Organizations (CROs), Hospitals and Clinics, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing application of cell & gene therapy in cancer research
      • 5.1.1.2. Rising prevalence of chronic disease across the globe
      • 5.1.1.3. Increasing investment activities by biopharmaceutical companies for cell-based research
    • 5.1.2. Restraints
      • 5.1.2.1. Technological complexity of delivering genes into the human body safely and effectively
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing regulatory approvals from the government for cell & gene therapies
      • 5.1.3.2. Increasing adoption of advanced technologies for cell & gene therapy clinical trials
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with variability in patient responses to therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising significance of allogeneic cell therapy in the treatment of cancers and genetic disorders
    • 5.2.2. End-User: Increasing application of cell & gene therapy clinical trials in contract research organizations due to their efficiency and scalability
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Clinical Trials Market, by Type

  • 6.1. Introduction
  • 6.2. Cell Therapy Clinical Trials
    • 6.2.1. Allogeneic Cell Therapy
    • 6.2.2. Autologous Cell Therapy
    • 6.2.3. CAR-T Cell Therapy
    • 6.2.4. Mesenchymal Stem Cell Therapy
  • 6.3. Gene Therapy Clinical Trials
    • 6.3.1. Antisense Oligonucleotide-Based Gene Therapy
    • 6.3.2. CRISPR-Based Gene Therapy
    • 6.3.3. Non-Viral Vector Gene Therapy
    • 6.3.4. Viral Vector Gene Therapy

7. Cell & Gene Therapy Clinical Trials Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Cell & Gene Therapy Clinical Trials Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Dermatology
  • 8.4. Endocrine, Metabolic, & Genetic
  • 8.5. Gastroenterology
  • 8.6. Hematology
  • 8.7. Immunology & Inflammation
  • 8.8. Infectious Diseases
  • 8.9. Musculoskeletal
  • 8.10. Neurology
  • 8.11. Oncology
  • 8.12. Ophthalmology

9. Cell & Gene Therapy Clinical Trials Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Contract Research Organizations (CROs)
  • 9.4. Hospitals and Clinics
  • 9.5. Pharmaceutical Companies

10. Americas Cell & Gene Therapy Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell & Gene Therapy Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Clinical Trials Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Cincinnati Children's launches USD 60 million Applied Gene and Cell Therapy Center in Sharonville
    • 13.3.2. Strategic partnership between Premier Research and BioCentriq accelerates pre-IND timelines and clinical translation of innovative cell therapies
    • 13.3.3. Astellas Pharma invests USD 50 million in Poseida Therapeutics for exclusive licensing and cancer cell therapy development
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accell Clinical Research, LLC
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. Amgen Inc.
  • 4. Atlant Clinical Ltd.
  • 5. Biogen Inc.
  • 6. Charles River Laboratories International, Inc.
  • 7. CORESTEM, Inc.
  • 8. CTI Clinical Trial and Consulting Services, Inc.
  • 9. Dendreon Pharmaceuticals LLC
  • 10. HELIXMITH Co., Ltd.
  • 11. ICON PLC
  • 12. IQVIA Inc.
  • 13. Kolon TissueGene, Inc.
  • 14. Laboratory Corporation of America Holdings
  • 15. Medpace Holdings, Inc.
  • 16. Novartis AG
  • 17. Novotech Pty Limited
  • 18. Parexel International Corporation
  • 19. Ppd, Inc.
  • 20. ProPharma Group Holdings, LLC
  • 21. PSI CRO
  • 22. SGS S.A.
  • 23. Syneos Health, Inc.
  • 24. Veristat, LLC
  • 25. Wuxi AppTec Inc.